RespiDx has developed a technology platform for a comprehensive physiological check-up, including cardio, respiratory and vital-signs data (and more). These signs include oral temperature, skin temperature, respiratory rate, heart rate, and oxygen saturation, respiratory/lung sounds (like a stethoscope), 6-lead ECG and more.
RespiDx is a social impact venture created to address to address one of the major health challenges in the developing world: The #1 killer of under-fives in low-resource areas is preventable pneumonia – responsible for the deaths of 900,000 kids annually in these areas, where they live with no doctors, and no X-ray machines. The only medical resource in these impoverished areas is CHWs, untrained community health workers. These CHWs have the required antibiotics (from UNICEF) but lack a working diagnostic tool. RespiDx has developed a simple thermometer-like tool for these CHWs, that provides a simple yes/no diagnosis of pneumonia and shows the result by lighting a red/green LED. This device has undergone proof-of-concept testing in clinical trials in the Congo and is now ready for optimization and scale-up. This work will be performed together with the University of Alberta, Canada and in collaboration with RespiDx’s partner in Kenya, Living Goods https://livinggoods.org/, and their funders at the Bill and Melinda Gates Foundation. RespiDx has received $400K investment in funding from Development Innovation Ventures (USAID) and Grand Challenges organizations.
OmnySense was spun out of RepiDx to commercialize its platform to create a thermometer-shaped device, the MultimometerTM, which performs a complete medical check-up during the 30 seconds required to take the patient’s temperature. This device will target Western markets, with the goal of determining if their child or baby is sick. This medical-grade information is stored in the cloud and enables a remote physician to perform a check-up while in video-conference with the patient. OmnySense’s cloud-based storage and rule-based algorithms will enable relatives to monitor their elderly parents and automatic alerts to be generated. The Multimometer is a game changer for the telemedicine/home care market, as it solves three main problems: simplicity/compliance (for patients), quality (for physicians) and costs (for payers).
OmnySense is currently raising a total of $3m in two stages, to bring the Multimometer product into clinical phase, and RespiDx seeks $500K from a social impact investor in order to finalize the pneumonia-diagnosis device. The RespiDx/OmnySense team is headed by a team of Israeli serial entrepreneurs with several “exits” to their name and supported by an internationally-renowned Advisory Board.